Genscript Biotech Corporation GNNSF
4.50 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
4.50 Day range 4.50
1.30 52-week range 6.55
- YTD
- +171.08%
- 1 year
- +114.29%
- Market cap
- 10.26B
- EPS (ttm)
- -0.29
- YTD return
- +171.08%
- 1-year return
- +114.29%
- Volume
- 250
- Avg volume
- 1.37K
- Open
- 4.50
- Previous close
- 4.50
- Day's range
- 4.50 – 4.50
- 52-week range
- 1.30 – 6.55
1Y +2.40 (+114.29%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 15, 2026 | Dec 31, 2025 | -0.03 | -0.23 | -0.20 | -666.67% |
| Aug 17, 2025 | Jun 30, 2025 | 0.08 | -0.0216 | -0.10 | -127.00% |
| Mar 11, 2025 | Dec 31, 2024 | -0.01 | 1.48 | +1.49 | +14,900.00% |
| Aug 9, 2024 | Jun 30, 2024 | -0.01 | -0.0827 | -0.07 | -727.00% |
| Mar 10, 2024 | Dec 31, 2023 | -0.05 | -0.032 | +0.02 | +36.00% |
News
Genscript Biotech Corporation (GNNSF) Q2 2026 Earnings Call Transcript 
Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript 
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth 
Genscript Biotech Corporation (GNNSF) Q2 2025 Earnings Call Transcript 
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation 
GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader 
GenScript Biotech Corporation Reports FY 2024 Results 
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development 
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia 
GenScript Biotech Corporation (GNNSF) Q2 2024 Earnings Call Transcript
Your note
Sign in to keep a note on GNNSF — it syncs with the Stock Master app.